CD276 and familial pancreatic carcinoma: B7-H3 is transcriptionally regulated by BRD4 in pancreatic cancer cells, and targeting the BRD4/B7-H3/TLR4 axis may be a novel therapeutic strategy to overcome chemotherapy resistance in pancreatic cancer [66].